Engineering ACE2 decoy receptors to combat viral escapability

Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape because viruses that require entry receptors cannot help but bind decoy receptors. Angiotensin-converting enzyme 2 (ACE2) is the major receptor for coronavirus cell entry. Recombinant soluble ACE2 was previously developed as a biologic against acute respiratory distress syndrome (ARDS) and verified to be safe in clinical studies. The emergence of COVID-19 reignited interest in soluble ACE2 as a potential broad-spectrum decoy receptor against coronaviruses. In this review, we summarize recent developments in preclinical studies using various high-affinity mutagenesis and Fc fusion approaches to achieve therapeutic efficacy of recombinant ACE2 decoy receptor against coronaviruses. We also highlight the relevance of stimulating effector immune cells through Fc-receptor engagement and the potential of using liquid aerosol delivery of ACE2 decoy recep-tors for defense against ACE2-utilizing coronaviruses.

Automated summary

This review summarizes recent developments in preclinical studies utilizing recombinant ACE2 decoy receptors against coronaviruses, highlighting the potential therapeutic efficacy achieved through various high-affinity mutagenesis and Fc fusion approaches. The relevance of stimulating effector immune cells and using liquid aerosol delivery for defense against ACE2-utilizing coronaviruses is also emphasized.